7月24日 - ** 基因疗法开发商Rocket Pharmaceuticals RCKT.O股价盘前上涨1.8%至3.42美元
** 公司称正在裁员约30%，12个月的现金消耗减少近25
** 补充说，该公司正在重组其药物开发项目，将重点放在心血管疗法和主要基因疗法候选药物 kresladi 上，后者正在开发中，用于治疗一种叫做严重白细胞粘附缺乏症的罕见免疫缺陷疾病。
** 截至最后收盘，股价累计下跌 73.3
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.